IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 239 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $26,876,104 | +147.9% | 5,906,836 | +283.6% | 0.06% | +129.2% |
Q2 2023 | $10,840,241 | -35.1% | 1,539,807 | -43.7% | 0.02% | -42.9% |
Q1 2023 | $16,714,430 | +1855.6% | 2,735,586 | +1945.2% | 0.04% | +2000.0% |
Q4 2022 | $854,688 | -96.1% | 133,754 | -94.2% | 0.00% | -97.0% |
Q3 2022 | $21,924,000 | +11.6% | 2,288,532 | +28.6% | 0.07% | +4.7% |
Q2 2022 | $19,644,000 | -39.0% | 1,779,389 | -8.0% | 0.06% | -36.6% |
Q1 2022 | $32,201,000 | +18.2% | 1,934,024 | +35.5% | 0.10% | +8.6% |
Q4 2021 | $27,239,000 | -29.6% | 1,426,835 | -9.0% | 0.09% | -42.2% |
Q3 2021 | $38,678,000 | +120.5% | 1,568,460 | +132.7% | 0.16% | +94.0% |
Q2 2021 | $17,540,000 | +231.1% | 674,124 | +302.9% | 0.08% | +219.2% |
Q1 2021 | $5,297,000 | +73.0% | 167,312 | +153.5% | 0.03% | +52.9% |
Q4 2020 | $3,062,000 | -94.0% | 66,000 | -95.8% | 0.02% | -95.5% |
Q3 2020 | $51,449,000 | +12387.6% | 1,562,864 | +10319.1% | 0.38% | +9325.0% |
Q2 2020 | $412,000 | -97.5% | 15,000 | -97.3% | 0.00% | -98.0% |
Q1 2020 | $16,793,000 | +4551.8% | 560,979 | +1375.8% | 0.20% | +9850.0% |
Q1 2019 | $361,000 | -20.1% | 38,011 | -25.6% | 0.00% | -33.3% |
Q4 2018 | $452,000 | -72.2% | 51,115 | -64.6% | 0.00% | -57.1% |
Q3 2018 | $1,623,000 | +261.5% | 144,287 | +311.3% | 0.01% | +250.0% |
Q2 2018 | $449,000 | – | 35,077 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 3,876,600 | $127,618,000 | 11.48% |
Fairmount Funds Management LLC | 596,890 | $19,650,000 | 8.32% |
Ghost Tree Capital, LLC | 575,000 | $18,929,000 | 5.47% |
Perceptive Advisors | 10,085,632 | $332,019,000 | 4.85% |
Avoro Capital Advisors LLC | 9,536,039 | $313,926,000 | 4.46% |
FRAZIER MANAGEMENT LLC | 1,312,999 | $43,224,000 | 3.88% |
ACUTA CAPITAL PARTNERS, LLC | 315,000 | $10,370,000 | 2.82% |
Orbimed Advisors | 6,645,100 | $218,757,000 | 2.75% |
QVT Financial LP | 572,971 | $18,862,000 | 2.30% |
Prosight Management, LP | 120,606 | $3,970,000 | 1.89% |